Analyst Price Targets — ALT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 22, 2026 10:30 am | Thomas Smith | Leerink Partners | $10.00 | $3.01 | TheFly | Altimmune initiated with an Outperform at Leerink |
| April 24, 2026 9:10 am | Corinne Johnson | Goldman Sachs | $2.50 | $2.89 | TheFly | Altimmune upgraded to Neutral from Sell at Goldman Sachs |
| January 27, 2026 9:11 pm | — | Barclays | $20.00 | $6.18 | TheFly | Altimmune initiated with an Overweight at Barclays |
| April 2, 2024 6:42 am | Patrick Trucchio | H.C. Wainwright | $12.00 | $10.23 | StreetInsider | Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report |
| December 1, 2022 5:36 am | — | Goldman Sachs | $20.00 | $9.95 | Benzinga | Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20 |
| November 11, 2022 8:29 am | — | JMP Securities | $26.00 | $11.12 | Benzinga | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26 |
| August 31, 2022 11:00 am | — | Jefferies | $35.00 | $22.08 | Benzinga | Jefferies Maintains Buy on Altimmune, Raises Price Target to $35 |
| August 30, 2022 8:40 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $18.94 | TheFly | Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler |
| August 17, 2022 6:36 am | — | H.C. Wainwright | $50.00 | $17.66 | Benzinga | HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50 |
Latest News for ALT
Shares of Altimmune, Inc. (NASDAQ: ALT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,045,926 shares of the company's stock after purchasing an additional 762,223 shares during the quarter. Dimensional Fund Advisors
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALT.
U.S. House Trading
No House trades found for ALT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.